Skip to main content

Multiple Sclerosis FENtrepid

Status: Closed to Enrollment

Study Details

View study details on clinicaltrials.gov.

Locations

  • Sunnyvale
  • Berkeley
  • Palo Alto

Clinical Trial FAQs

Information for patients and study volunteers, including frequently asked questions.

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis (FENtrepid)

A Multiple Sclerosis study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS). All eligible participants will be randomized 1:1 to either daily oral fenebrutinib (or placebo) or intravenous (IV) ocrelizumab (or placebo) in a blinded fashion. Approximately 946 participants will be enrolled and will be recruited globally.

Ariele L Greenfield
Ariele L Greenfield
Principal investigator
View Profile

Funder

F. Hoffman-La Roche Ltd

You're leaving our site

The website you have selected is an external one located on another server. This website may contain links to third party sites. These links are provided for convenience purposes and are not under the control of Sutter Health. Do you wish to continue?